A Study of IVX-A12 in Adults Participants

RSV-F Vaccine Dose Ranging Study in Young Women

NCT01704365 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502 ·Status: COMPLETED ·Phase: PHASE3

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

NCT06556147 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

NCT07117487 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

NCT02491463 ·Status: COMPLETED ·Phase: PHASE1

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

NCT06067230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

NCT06389487 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

NCT06473519 ·Status: COMPLETED ·Phase: PHASE3

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

NCT06134648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

NCT05590403 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

NCT03814590 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

NCT02296463 ·Status: COMPLETED ·Phase: PHASE1

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

NCT03982199 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine

NCT02472548 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

NCT02298179 ·Status: COMPLETED ·Phase: PHASE1

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

NCT06077149 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

NCT03572062 ·Status: TERMINATED ·Phase: PHASE2

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

NCT06251024 ·Status: COMPLETED ·Phase: PHASE2

RSV Immunogenicity Study in the Elderly (RISE)

NCT07203365 ·Status: RECRUITING ·Phase: PHASE3

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT02601612 ·Status: COMPLETED ·Phase: PHASE1

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

NCT06645665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1